Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited Fundamental Analysis
Gujarat Themis Biosyn Limited (GUJTHEM.BO) shows moderate financial fundamentals with a PE ratio of 71.43, profit margin of 30.00%, and ROE of 19.41%. The company generates $1.6B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 73.8/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze GUJTHEM.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentGUJTHEM.BO demonstrates superior asset utilization.
Valuation Score
ModerateGUJTHEM.BO shows balanced valuation metrics.
Growth Score
ModerateGUJTHEM.BO shows steady but slowing expansion.
Financial Health Score
ExcellentGUJTHEM.BO maintains a strong and stable balance sheet.
Profitability Score
ModerateGUJTHEM.BO maintains healthy but balanced margins.
Key Financial Metrics
Is GUJTHEM.BO Expensive or Cheap?
P/E Ratio
GUJTHEM.BO trades at 71.43 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, GUJTHEM.BO's PEG of -63.28 indicates potential undervaluation.
Price to Book
The market values Gujarat Themis Biosyn Limited at 12.91 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 44.50 times EBITDA. This signals the market has high growth expectations.
How Well Does GUJTHEM.BO Make Money?
Net Profit Margin
For every $100 in sales, Gujarat Themis Biosyn Limited keeps $30.00 as profit after all expenses.
Operating Margin
Core operations generate 38.98 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $19.41 in profit for every $100 of shareholder equity.
ROA
Gujarat Themis Biosyn Limited generates $12.69 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Gujarat Themis Biosyn Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Gujarat Themis Biosyn Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
GUJTHEM.BO converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
71.43
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-63.28
vs 25 benchmark
P/B Ratio
Price to book value ratio
12.91
vs 25 benchmark
P/S Ratio
Price to sales ratio
21.43
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.27
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.47
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.19
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.18
vs 25 benchmark
How GUJTHEM.BO Stacks Against Its Sector Peers
| Metric | GUJTHEM.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 71.43 | 29.78 | Worse (Expensive) |
| ROE | 19.41% | 792.00% | Weak |
| Net Margin | 30.00% | -24634.00% (disorted) | Strong |
| Debt/Equity | 0.27 | 0.25 | Neutral |
| Current Ratio | 1.47 | 4.60 | Neutral |
| ROA | 12.69% | -18106.00% (disorted) | Strong |
GUJTHEM.BO outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Gujarat Themis Biosyn Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation